ABIEL SOCIETA A RESPONSABILITA LIMITATA

Their core work

ABIEL is a Palermo-based SME specializing in bio-material engineering, with particular expertise in designing artificial fluorescent proteins and bio-hybrid photonic systems. Their work spans the intersection of biotechnology and advanced materials — from biomedical implant development (diabetes-reversing devices) to engineered protein-based light-emitting diodes. They contribute specialized material science and protein engineering capabilities to European research consortia focused on translating biological building blocks into functional devices.

What they specialise in

How they've shifted over time

ABIEL's early H2020 activity (2015-2018) centered on biomedical applications — diabetes implants and pharmaceutical formulations — suggesting a foundation in biomaterials for health. Their most recent project, ARTIBLED (2020-2024), marks a clear pivot toward bio-photonics: engineering artificial proteins to create biological light-emitting diodes. This shift from health-oriented biomaterials to functional photonic bio-materials shows a deliberate move toward the emerging field where biology meets optoelectronics.

ABIEL is moving from passive biomaterial roles in health projects toward active bio-photonic material design, positioning them at the frontier of protein-based optoelectronic devices.

How they like to work

ABIEL operates exclusively as a consortium participant — they have never coordinated an H2020 project. Across 3 projects they have worked with 25 unique partners in 9 countries, indicating they join moderately large, internationally diverse consortia. Their role pattern suggests they bring specialized material science capabilities to larger teams rather than driving project direction themselves.

ABIEL has built a network of 25 partners across 9 European countries through just 3 projects, reflecting participation in broad, multi-national consortia. Their network is wide relative to their project count, suggesting they are embedded in well-connected research communities.

What sets them apart

ABIEL sits at an unusual intersection: a small Italian company that bridges biomedical materials and bio-photonics. Their trajectory from health implants to protein-engineered LEDs gives them cross-domain fluency that few SMEs possess — they understand both biological functionality and material device integration. For consortium builders, they offer specialized bio-material fabrication capabilities without the overhead of a large research institute.

Highlights from their portfolio

• ARTIBLED
  Their most technically distinctive project — engineering artificial fluorescent proteins into biological LEDs represents a genuinely niche capability at the biology-photonics boundary.
• DRIVE
  Their largest single EC contribution (EUR 887,366) and earliest project, focused on diabetes-reversing implants with long-term viability — a high-impact biomedical challenge.